Drugmaker Arcutis jumps on rise in Q1 revenue

Arcutis Biotherapeutics

15/05/2024 09:56

** Shares of drugmaker Arcutis Biotherapeutics  ARQT.O  rise
18.3% to $9.62 premarket
    ** Co posts Q1 revenue of $49.6 mln vs $2.8 mln a year
earlier
    ** ARQT reports Q1 net product revenue of $21.6 mln from its
psoriasis and eczema treatment cream Zoryve vs $2.8 mln a year
earlier
    ** Posts Q1 net loss of $35.4 mln vs loss of $80.1 mln a
year earlier
    ** Up to last close, stock has more than doubled YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))